Bexarotene PO monotherapy for CTCL (300 mg/m² daily, continuous)

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Components	`DRUG-BEXAROTENE`

ID	`REG-BEXAROTENE-MONO-CTCL`
Type	Regimen
Status	reviewed 2026-04-27 \| pending_clinical_signoff
Diseases	None declared
Sources	`SRC-ESMO-CTCL-2024` `SRC-NCCN-BCELL-2025`

Notes

Duvic 2001 (Arch Dermatol) — ORR 45-55% in r/r CTCL. Triglyceride and thyroid management are dominant practical concerns; statin/ fibrate prophylaxis effectively recommended from day 1. Suitable for both 2L (active disease control) and maintenance settings. Topical gel formulation useful for limited skin involvement.

Used By

Indication

IND-MF-ADVANCED-2L-BEXAROTENE - IND-MF-ADVANCED-2L-BEXAROTENE